Bio-Thera & Dr Reddy’s execute commercialization pact for biosimilars Stelara & Simponi for SE Asia
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
The OPTASE range is a safe, tested and expert recommended 3-step regime to help tackle the cause and symptoms of eye conditions
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Cyclosporine Ophthalmic Nanoemulsion is a preservative-free Nanoemulsion that has been approved in South Korea, Peru and several countries in the Middle East for treatment of dry eye syndrome
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America
Subscribe To Our Newsletter & Stay Updated